骨质注射到乳腺脂肪垫：在小鼠中建立乳腺癌

Executive Industry Relevance

Establishing physiologically relevant breast cancer models is critical for preclinical target validation and therapeutic screening. Orthotopic injection into the mammary fat pad enables tumor growth in a native microenvironment, improving predictive confidence in drug efficacy and mechanistic de-risking. This approach supports early discovery workflows by providing a disease-relevant system for evaluating lead compounds and pathway modulation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses in a native tumor microenvironment, supporting biological de-risking of targets.
• Operational Value: Generates reproducible tumor models for consistent pathway interrogation across screening campaigns.
• Strategic Value: Improves target confidence by linking molecular perturbations to phenotypic tumor growth in vivo.

Screening & Assay Development

• Scientific Value: Produces quantifiable tumor growth signals via luciferase expression, enabling longitudinal monitoring of therapeutic response.
• Operational Value: Standardizes cell delivery technique to reduce variability in engraftment efficiency across compound testing.
• Strategic Value: Supports assay readiness for high-throughput in vivo screening by establishing a reliable engraftment workflow.

Translational & Preclinical Research

• Scientific Value: Maintains disease relevance by modeling tumor-stroma interactions in the mammary fat pad, improving translational biomarker alignment.
• Operational Value: Facilitates continuity from target validation to preclinical efficacy studies using the same orthotopic model.
• Strategic Value: Enables risk-adjusted advancement decisions by capturing microenvironment-dependent drug responses.

Pipeline & Workflow Integration

The orthotopic mammary fat pad injection method integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, providing a reproducible in vivo readout for therapeutic evaluation.

• Discovery Biology: Supports hypothesis testing by enabling functional validation of oncogenic pathways in a physiologically contextualized tumor model.
• Screening: Delivers standardized tumor engraftment for consistent compound evaluation in vivo, reducing false negatives from variable take rates.
• Analytics: Generates bioluminescent imaging readouts that quantify tumor burden over time, enabling longitudinal pharmacodynamic assessments.
• Translational Research: Connects early target modulation to phenotypic tumor outcomes in a disease-relevant system, supporting biomarker-driven go/no-go decisions.
• Enterprise Reuse: Establishes a reusable engraftment platform applicable across multiple breast cancer cell lines and therapeutic modalities.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence by modeling tumor growth in a native stromal context, reducing mechanistic ambiguity in target validation.
• Operational Value: Improves reproducibility through standardized surgical technique and cell preparation protocols.
• Strategic Value: Increases capital efficiency by improving engraftment success rates, reducing animal use per informative data point.
• Portfolio Impact: Enables risk-based prioritization of leads by linking in vivo efficacy to target modulation in a physiologically relevant model.

Implementation Considerations

• Requires expertise in rodent handling, aseptic technique, and microsurgical injection skills.
• Dependent on sterile microsyringes, fine-gauge needles, and bioluminescent imaging infrastructure.
• Necessitates cross-team standardization between animal care, compound delivery, and imaging teams.
• Must account for variability in mammary fat pad anatomy across mouse strains and ages.
• Limited by technical skill dependency; improper injection can result in ectopic engraftment or failed tumor take.

Biopharma FAQs